erlotinib hydrochloride has been researched along with sulindac in 6 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (sulindac) | Trials (sulindac) | Recent Studies (post-2010) (sulindac) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 1,462 | 202 | 305 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | sulindac (IC50) |
|---|---|---|---|
| Aldo-keto reductase family 1 member B10 | Homo sapiens (human) | 2.69 | |
| Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | 2.69 | |
| Aldo-keto reductase family 1 member B1 | Bos taurus (cattle) | 0.293 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 8.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Argiris, A; Ferris, RL; Freilino, ML; Gooding, WE; Grandis, JR; Gross, N; Moskowitz, HS; Thomas, SM | 1 |
| Argiris, A; Bauman, JE; Chiosea, S; Conrads, TP; Denq, W; Ferris, RL; Flint, MS; Gooding, WE; Grandis, JR; Gross, ND; Hood, BL; Johnson, JT; Kim, S; Nikiforova, MN; Siegfried, JM; Sun, M; Thomas, SM; Wang, L; Wirth, L | 1 |
| Baker, H | 1 |
| Berry, T; Boucher, KM; Burt, RW; Byrne, K; Jasperson, K; Jones, D; Kanth, P; Kuwada, SK; Neklason, DW; Pappas, L; Samadder, NJ; Samowitz, W; Sample, D; Smith, L; Tavtigian, SV; Westover, M | 1 |
| Burke, CA; Chick, RC; Cindass, JL; Clifton, GT; Ensley, DC; Hale, DF; Hickerson, AT; Kemp Bohan, PM; Mankaney, G; Peoples, GE; Sohn, V; Vreeland, TJ | 1 |
| Brown, PH; Dashwood, RH; Dashwood, WM; Gustafson, TA; Kapoor, S; Mohammed, A; Rajendran, P; Savage, MI; Sei, S; Ulusan, AM; Vilar, E; Yavuz, OF | 1 |
1 review(s) available for erlotinib hydrochloride and sulindac
| Article | Year |
|---|---|
Chemoprevention in familial adenomatous polyposis: past, present and future.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antineoplastic; Ascorbic Acid; Aspirin; Capsules; Celecoxib; Chemoprevention; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Eflornithine; Erlotinib Hydrochloride; Fatty Acids, Nonesterified; Genes, APC; Humans; Sirolimus; Sulindac; TOR Serine-Threonine Kinases; Vitamins | 2021 |
3 trial(s) available for erlotinib hydrochloride and sulindac
| Article | Year |
|---|---|
Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Hepatocyte Growth Factor; Humans; Interleukin-6; Male; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Placebos; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sulindac; Transforming Growth Factor alpha | 2012 |
Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cohort Studies; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Sulindac; Tissue Array Analysis | 2014 |
Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Sulindac; Treatment Outcome | 2018 |
2 other study(ies) available for erlotinib hydrochloride and sulindac
| Article | Year |
|---|---|
Sulindac plus erlotinib for familial adenomatous polyposis.
Topics: Adenomatous Polyposis Coli; Antineoplastic Combined Chemotherapy Protocols; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Sulindac | 2016 |
Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP).
Topics: Adenomatous Polyposis Coli; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colonic Polyps; Disease Models, Animal; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Genes, APC; Intestinal Neoplasms; Male; Mutation; Rats; Sulindac | 2021 |